Page 182 - 2020_07-Haematologica-web

T.A. Eyre et al. References
1. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multi- center study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017; 75:195-203.
2. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- and post-rituximab. Ann Hematol. 2011; 90(7):809-818.
3. Cabannes-Hamy A, Peyrade F, Jardin F, et al. Central nervous system relapse in patients over 80 years with diffuse large B- cell lymphoma: an analysis of two LYSA studies. Cancer Med. 2018;7(3):539-548.
4. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index : A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150- 3156.
5. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophy- laxis. A systematic review of prospective studies. Clin Lymphoma, Myeloma Leuk. 2015;15(8):451-457.
6. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nerv- ous system recurrence in aggressive lym- phoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149- 157.
7. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nerv- ous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high- risk patients with diffuse large B-cell lym- phoma. Cancer. 2010;116(18):4283-4290.
8. Ferreri AJM, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015; 168 (5):654-662.
9. Cheah CY, Herbert KE, O’Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strate- gies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014; 111(6):1072-1079.
10. Mcmillan A, Ardeshna KM, Cwynarski K, Lyttelton M, Mckay P, Montoto S. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163(2):168-181.
11. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915-1925.
12. Pui C-H, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360 (26):2730-2741.
13. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue pro- files after ventriculocisternal perfusion. J
Pharmacol Exp Ther. 1975;195(1):73-83. 14. De la Riva P, Andres-Marín N, Gonzalo- Yubero N, et al. Headache and other com- plications following intrathecal chemother- apy administration. Cephalalgia. 2016;
37(11):1109–1110.
15. Coiffier B, Lepage E, Briere J, et al. CHOP
chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. 2002; 346(4):235-242.
16. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with dif- fuse large B-cell lymphoma: A systematic review and meta-Analysis. Leuk Lymphoma. 2014;55(3):509-514.
17. Guirguis HR, Cheung MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk fac- tors for CNS relapse in patients with dif- fuse large B-cell lymphoma treated in the rituximab era: A single centre experience and review of the literature. Br J Haematol. 2012;159(1):39-49.
18. Mitrovic Z, Bast M, Bierman PJ, et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol 2012;157(3):401-403.
19. Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B- cell lymphoma. Ann Oncol. 2007; 18(3):541-545.
20. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocorti- sone reduces central nervous system recur- rence and improves survival in aggressive non-Hodgkin lymphoma. Cancer. 2002; 95(3):576-580.
21. Grant MJ, Booth A. A typology of reviews: An analysis of 14 review types and associ- ated methodologies. Health Info Libr J. 2009;26(2):91-108.
22. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRIS- MA-P) 2015 statement. Syst Rev. 2016;4:1.
23. Avilés A, Jesús Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lym- phoma: An analysis of 3,258 patients in a single center. Med Oncol. 2013;30(2):520- 526.
24. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926.
25. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nerv- ous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemother- apy. Ann Oncol. 2009;21(5):1046-1052.
26. Malecek MK, Petrich AM, Rozell S, et al. Frequency, risk factors, and outcomes of central nervous system relapse in lym- phoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol. 2017;92(11):1156-1162.
27. Gleeson M, Counsell N, Cunningham D, et
al. Central nervous system relapse of dif- fuse large B-cell lymphoma in the ritux- imab era: Results of the UK NCRI R- CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516.
28. Kanemasa Y, Shimoyama T, Sasaki Y, et al. Central nervous system relapse in patients with diffuse large B cell lymphoma: analy- sis of the risk factors and proposal of a new prognostic model. Ann Hematol. 2016; 95(10):1661-1669.
29. Kumar A, Vanderplas A, Lacasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lym- phoma in the rituximab era: Findings from a large national database. Cancer. 2012;118(11):2944-2951.
30. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lym- phoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOV- ER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896- 3902.
31. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: Prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol. 2009;89(5):577-583.
32. Song YS, Lee WW, Lee JS, Kim SE. Prediction of central nervous system relapse of diffuse large B-cell lymphoma using pretherapeutic [18F]2-fluoro-2- deoxyglucose (FDG) positron emission tomography/computed tomography. Medicine (Baltimore). 2015;94(44):e1978.
33. Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma follow- ing rituximab plus cyclophosphamide, dox- orubicin, vincristine and prednisone. Leuk Lymphoma. 2015;56(3):725-729.
34. Cai QQ, Hu LY, Geng QR, et al. New risk factors and new tendency for central nerv- ous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Chin J Cancer. 2016;35(1):87.
35. Wudhikarn K, Bunworasate U, Julamanee J, et al. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry. Ann Hematol. 2017;96(1):57-64.
36. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503-1510.
37. Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rit- uximab era. Cancer Sci. 2012;103(2):245-251.
38. Eyre TA, Kirkwood AA, Wolf J, et al. Stand- alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br J Haematol. 2019;187(2):185- 194.
1924
haematologica | 2020; 105(7)